| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/ECP.11.29 |
| P8608 | Fatcat ID | release_bqqt64xd4bcrvdrha6dsx3dl3e |
| P698 | PubMed publication ID | 22114855 |
| P5875 | ResearchGate publication ID | 51828238 |
| P2093 | author name string | Kathleen Uhl | |
| Douglas C Throckmorton | |||
| Emmanuel O Fadiran | |||
| Ameeta Parekh | |||
| P2860 | cites work | Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000-2002. | Q50109603 |
| Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart | Q51007577 | ||
| Increasing participation of women in early phase clinical trials approved by the FDA. | Q51651575 | ||
| Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. | Q51826453 | ||
| Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender | Q56944785 | ||
| Phenylpropanolamine and the risk of hemorrhagic stroke | Q31704504 | ||
| Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome | Q34323705 | ||
| Historical background of clinical trials involving women and minorities | Q34333021 | ||
| The role of the NIH's Office of Research on Women's Health | Q34333026 | ||
| Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. | Q34387461 | ||
| Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). | Q34587610 | ||
| Dofetilide: a new class III antiarrhythmic agent | Q34594440 | ||
| The FDA critical path initiative and its influence on new drug development. | Q34734622 | ||
| Sex differences in pharmacokinetics and pharmacodynamics | Q35639177 | ||
| Diabetes drug pioglitazone (Actos): risk of fracture | Q35991210 | ||
| Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics | Q36030574 | ||
| The current state of knowledge on age, sex, and their interactions on clinical pharmacology | Q36818908 | ||
| Perspectives on early communication of drug risks to the public | Q37374196 | ||
| Sex differences in pharmacokinetics and pharmacodynamics | Q40398634 | ||
| A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects | Q42676120 | ||
| Drug-induced QT prolongation in women during the menstrual cycle | Q43545871 | ||
| Historical background of changes in FDA policy on the study and evaluation of drugs in women | Q46761272 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 453-466 | |
| P577 | publication date | 2011-07-01 | |
| P1433 | published in | Expert Review of Clinical Pharmacology | Q15793519 |
| P1476 | title | Adverse effects in women: implications for drug development and regulatory policies | |
| P478 | volume | 4 |
| Q43763549 | A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal |
| Q36218118 | Comparative Toxicity by Sex Among Children Treated for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group |
| Q39077202 | Drugs and Medical Devices: Adverse Events and the Impact on Women's Health |
| Q61774363 | Epilogue: Future of Sex and Gender-Based Studies in Infectious Diseases |
| Q55115343 | Factors influencing the willingness to participate in medical research: a nationwide survey in Taiwan. |
| Q47224501 | Gender differences in clinical registration trials; is there a real problem? |
| Q39193538 | Gender differences in the effects of cardiovascular drugs |
| Q92471025 | Gender inequality and restrictive gender norms: framing the challenges to health |
| Q47920504 | Glial source of nitric oxide in epileptogenesis: A target for disease modification in epilepsy. |
| Q56880208 | How health equity is reported and analyzed in randomized trials |
| Q33823692 | Inclusion of sex and gender in biomedical research: survey of clinical research proposed at the University of Pennsylvania. |
| Q46593394 | Personalized vaccinology: one size and dose might not fit both sexes |
| Q46569836 | Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015. |
| Q89670151 | Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study |
| Q92419621 | Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus |
| Q38961758 | Sex as a Biological Variable: Who, What, When, Why, and How. |
| Q58577323 | Sex matters |
| Q94517996 | The impact of sex and gender on immunotherapy outcomes |
| Q100407801 | The scientific body of knowledge - Whose body does it serve? A spotlight on oral contraceptives and women's health factors in neuroimaging |
| Q89855858 | Tolerability of Antiseizure Medications in Individuals With Newly Diagnosed Epilepsy |
| Q36707031 | Women's involvement in clinical trials: historical perspective and future implications |
Search more.